LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) announced today that EndoBarrier® Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, will be the subject of several presentations and scientific sessions during Digestive Disease Week 2012 (DDW), taking place May 19-22 at the San Diego Convention Center in San Diego.
“There is ongoing interest in the use of EndoBarrier Therapy as demonstrated by the number of presentations offered at DDW and other medical conferences,” said Mark C. Twyman, chief commercial officer, GI Dynamics, Inc. “Patients with type 2 diabetes and/or obesity across the globe have achieved significant health improvements and treatment outcomes as a result of EndoBarrier Therapy. DDW is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, endoscopy and gastrointestinal surgery, and we look forward to sharing EndoBarrier demonstrations, clinical research and treatment insights with this important medical community.”
Alex Escalona, M.D., assistant professor of surgery, Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile, will provide an overview of EndoBarrier Therapy and present a hands-on demonstration of the device at the workshop, “Xtreme Endoscopic Toolbox: New and Cutting Edge Therapies,” on Sunday, May 20, 2012, from 7:30–10 a.m. PDT at the San Diego Convention Center in Hall H.
“EndoBarrier is a thin, flexible, sleeve-like liner that works by creating a physical barrier between food and a portion of the intestinal wall,” said Dr. Escalona. “With EndoBarrier Therapy, my patients report increased energy, feeling full for a longer period of time after eating, and immediate and continued weight loss. I look forward to sharing with my colleagues what EndoBarrier Therapy is, how it works, and how it is easily inserted and removed during this interactive session.”
In addition, clinical data for EndoBarrier Therapy will be highlighted at DDW during the following oral presentations:
|
Session: |
||||
| Presenter: |
Eduardo G. Moura, M.D., Ph.D., director of endoscopy, digestive surgery department, Hospital das Clinicas, University of Sao Paulo, Brazil |
|||
| Date: | Sunday, May 20, 2012, from 2:15-3:45 p.m. (PDT) | |||
| Location: | San Diego Convention Center - 10 | |||
|
Session: |
||||
| Presenter: |
Paulo Sakai, M.D., FASGE, associate professor, gastrointestinal endoscopy unit, University of Sao Paulo, Brazil |
|||
| Date: | Tuesday, May 22, 2012, from 3-5 p.m. (PDT) | |||
| Location: | San Diego Convention Center - 6ab | |||
About EndoBarrier
EndoBarrier Therapy is a breakthrough treatment for type 2 diabetes and/or obesity that has been clinically demonstrated to lower HbA1c levels, achieve weight loss of more than 20 percent, and improve important metabolic measures including cholesterol, blood sugar and triglycerides.1 It has been studied in 13 clinical trials and has been used in more than 500 patients. The EndoBarrier device is a thin, flexible, tube-shaped liner that forms a physical barrier between food and a portion of the wall of the intestine. EndoBarrier Therapy affects certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety, and these changes allow for rapid and sustained improvement of type 2 diabetes and weight loss.2
EndoBarrier received CE Mark approval for Europe in 2010 as well as approval by the Therapeutic Goods Administration in Australia in 2011 for the treatment of type 2 diabetes and/or obesity. EndoBarrier is currently commercially available in select European markets, Chile and Australia. For more information, please visit www.endobarrier.com.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The company’s flagship product, EndoBarrier®, is a novel, non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic patients and/or obese patients during the implant period. GI Dynamics currently markets EndoBarrier in select regions in Europe, South America and Australia and is planning near-term commercial expansion into additional European countries. EndoBarrier is not approved for sale in the United States and is considered investigational. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.
1 Moura, GHD, et al, One Year Results of an Endoscopic, Duodenal-Jejunal Exclusion Device for Weight Loss and Control of Type 2 Diabetes. Hospital das Clinicas, University of São Paulo, São Paulo, Brazil. DT&T, February 2012, vol 14, no.2:183-189.
2 C de Jonge, JW Greve, N Bouvy, et al, EndoBarrier Gastrointestinal Liner treatment rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients, Department of Surgery, Maastricht University Medical Centre, presented at IFSO 2011, Hamburg, Germany.